Europe ready to embrace first copies of biotech cancer drugs
February 15, 2017 at 05:01 AM EST
LONDON, Feb 15 (Reuters) - Treatment with two important cancer drugs is about to get much cheaper in Europe with a cut-price copy of Roche's blood cancer drug Rituxan likely to hit the market imminently followed by a rival to its breast cancer medicine Herceptin.
